Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $23.31 million. The enterprise value is -$11.98 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 31.93 million shares outstanding. The number of shares has increased by 2.06% in one year.
| Current Share Class | 31.93M |
| Shares Outstanding | 31.93M |
| Shares Change (YoY) | +2.06% |
| Shares Change (QoQ) | +1.23% |
| Owned by Insiders (%) | 6.94% |
| Owned by Institutions (%) | 14.00% |
| Float | 29.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.99 |
| Forward PS | 14.51 |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.92 |
| Quick Ratio | 6.53 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.57% and return on invested capital (ROIC) is -29.64%.
| Return on Equity (ROE) | -50.57% |
| Return on Assets (ROA) | -27.61% |
| Return on Capital (ROIC) | -29.64% |
| Revenue Per Employee | $47,232 |
| Profits Per Employee | -$266,350 |
| Employee Count | 155 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 1.28 |
Taxes
In the past 12 months, Co-Diagnostics has paid $3.90 million in taxes.
| Income Tax | 3.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.52% in the last 52 weeks. The beta is -0.91, so Co-Diagnostics's price volatility has been lower than the market average.
| Beta (5Y) | -0.91 |
| 52-Week Price Change | -36.52% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.19 |
| Relative Strength Index (RSI) | 24.08 |
| Average Volume (20 Days) | 187,104 |
Short Selling Information
The latest short interest is 228,278, so 0.71% of the outstanding shares have been sold short.
| Short Interest | 228,278 |
| Short Previous Month | 229,088 |
| Short % of Shares Out | 0.71% |
| Short % of Float | 0.77% |
| Short Ratio (days to cover) | 1.77 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $7.32 million and -$41.28 million in losses. Loss per share was -$1.38.
| Revenue | 7.32M |
| Gross Profit | 3.61M |
| Operating Income | -40.00M |
| Pretax Income | -35.81M |
| Net Income | -41.28M |
| EBITDA | -38.67M |
| EBIT | -40.00M |
| Loss Per Share | -$1.38 |
Full Income StatementBalance Sheet
The company has $37.66 million in cash and $2.37 million in debt, giving a net cash position of $35.29 million or $1.11 per share.
| Cash & Cash Equivalents | 37.66M |
| Total Debt | 2.37M |
| Net Cash | 35.29M |
| Net Cash Per Share | $1.11 |
| Equity (Book Value) | 63.78M |
| Book Value Per Share | 2.00 |
| Working Capital | 34.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.70 million and capital expenditures -$1.14 million, giving a free cash flow of -$26.84 million.
| Operating Cash Flow | -25.70M |
| Capital Expenditures | -1.14M |
| Free Cash Flow | -26.84M |
| FCF Per Share | -$0.84 |
Full Cash Flow StatementMargins
| Gross Margin | 49.30% |
| Operating Margin | -546.37% |
| Pretax Margin | -510.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.06% |
| Shareholder Yield | -2.06% |
| Earnings Yield | -177.12% |
| FCF Yield | -115.16% |
Analyst Forecast
The average price target for Co-Diagnostics is $1.50, which is 105.48% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.50 |
| Price Target Difference | 105.48% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of 1.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.07 |
| Piotroski F-Score | 2 |